Navigation Links
Caliper Life Sciences Reports First Quarter 2009 Results
Date:4/30/2009

losure.com or on the Caliper website at www.caliperLS.com in the Events section of the Investor Relations page. A webcast replay of the call will remain available until Caliper's earnings call for the second quarter of 2009.

Telephone replays of the conference call will be available approximately two hours after the completion of the call on April 30, 2009 through May 7, 2009. To access a telephone playback of the proceedings, dial 888.286.8010 and use the participant passcode 26367972. International callers can access the playback by dialing 617.801.6888 and using the same participant passcode.

About Caliper Life Sciences

Caliper Life Sciences is a premier provider of cutting-edge technologies enabling researchers in the life sciences industry to create life-saving and enhancing medicines and diagnostic tests more quickly and efficiently. Caliper is aggressively innovating new technology to bridge the gap between in vitro assays and in vivo results and then translating those results into cures for human disease. Caliper's portfolio of offerings includes state-of-the-art microfluidics, lab automation and liquid handling, optical imaging technologies, and discovery and development outsourcing solutions. For more information please visit www.caliperLS.com.

The statements in this press release regarding future events, including statements regarding Caliper's expectations regarding CDAS growth of revenue over the second half based upon the expectation that Caliper will receive a task order under the EPA ToxCast project, Caliper's expectation to deliver positive full year EBITDA in 2010, Caliper's expected revenue outlook for the second quarter ending June 30, 2009, and Caliper's expected organic growth rates for the second quarter, first half and full year results are "forward-looki
'/>"/>

SOURCE Caliper Life Sciences, Inc.
Copyright©2009 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10

Related biology technology :

1. VisEn Medical Files Action to Invalidate New Caliper Life Sciences Patent
2. Caliper Life Sciences Presentation at Thomas Weisel Partners Healthcare Conference to be Webcast
3. Caliper Life Sciences Introduces High Throughput RNA Assay to Improve Workflow in Gene Expression Studies
4. Caliper Life Sciences Presentation at UBS Global Life Sciences Conference to be Webcast
5. Caliper Life Sciences Awarded National Institute of Environmental Health Services Contract Valued to $7.0 Million
6. Caliper Life Sciences to Participate in Deutsche Banks Healthcare Technology Industry Day
7. Caliper Life Sciences Introduces Zephyr SPE Workstation to Improve Efficiency of Solid Phase Extraction
8. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference
9. Caliper Life Sciences to Present at JPMorgan 26th Annual Healthcare Conference Today
10. Caliper Life Sciences to Present at Deutsche Bank 2008 Small and Mid Cap Growth Conference
11. Caliper Life Sciences Fourth Quarter 2007 Financial Results Conference Call Notice
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:9/3/2015)... ... September 03, 2015 , ... UCLA wide receiver ... Conventional treatment and therapy were not working so Zach decided to undergo stem ... treated Zack with precisely guided injections of bone marrow aspirate concentrate (BMAC) harvested ...
(Date:9/3/2015)... SAN DIEGO , Sept. 3, 2015 /PRNewswire/ ... factors, and a recent spinout of Stemedica Cell ... Thomas H. Silberg as CEO of StemProtein. ... technology for producing and preserving Stem Cell Factors ... is a seasoned professional in the pharmaceutical and biopharmaceutical ...
(Date:9/3/2015)... ... September 03, 2015 , ... If you plan to ... Boston this October, you will also want to sign up for the tour of ... The tour includes a walk through of the (8) chemistry teaching labs that ...
(Date:9/2/2015)... Research and Markets ... Jain PharmaBiotech,s new report "DNA Sequencing - ... This report briefly reviews basics of ... their applications. Current large and small sequencers are ... applications of sequencing are described including those for ...
Breaking Biology Technology:UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 2UCLA Wide Receiver and Canadian Decathlon Standout Zack Bornstein Bounces Back After Stem Cell Therapy at Riordan-McKenna Institute 3StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 2StemProtein Names Thomas H. Silberg As CEO, To Focus On Stem Cell Secreted Proteins Addresing A Variety Of Health And Beauty Related Needs 3Erlab Invites You to Tour the Largest Installation of Filtered Fume Hoods in the World 2Global DNA Sequencing Technologies Report 2015: Profiles of 130 Companies Involved in Sequencing and their 140 Collaborations 2
... Nov. 5, 2011 Jennerex, Inc., a private clinical-stage ... of first-in-class targeted oncolytic products for cancer, today presented ... trial of JX-594 in patients with advanced liver cancer ... the high JX-594 dose group versus the low dose ...
... Corporation (OTCQX:RXPC) (OTCPK:RXPC), a developer and marketer of ... that all six proxy resolutions passed at a special ... statement was filed with the Securities and Exchange Commission ... and on the Company,s web site:   www.radient-pharma.com ...
... ZURICH, Switzerland, November 4, 2011 Major ... in the treatment of patients with refractory ascites due ... University of Vienna and Vienna General Hospital (AKH Wien) ... the ALFApump System were performed at Vienna General Hospital ...
Cached Biology Technology:Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 2Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 3Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 4Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 5Jennerex Presents Final Data From JX-594 Randomized Phase 2 Clinical Trial Showing Statistically Significant Survival Benefit in Patients With Advanced Liver Cancer 6Radient Pharmaceuticals Announces Proxy Resolutions Approved at Special Meeting of Stockholders 2The Medical University of Vienna and Vienna General Hospital Perform the First two Commercial Implants Worldwide of Sequana Medical's ALFApump® System 2
(Date:8/5/2015)... 2015 The biosensors market is proving highly ... into newer sectors, and development of devices resulting in ... has seen the entry of multiple participants each year ... (Photo - http://photos.prnewswire.com/prnh/20150805/255570 ) ... the Global Biosensors Market ( http://www.frost.com/nee9 ), finds ...
(Date:8/3/2015)... , Aug. 3, 2015 Synaptics, Inc. (Nasdaq: ... solutions, today announced that members of the executive management ... Pacific Crest Global Technology Leadership Forum on Tuesday, August ... will be held at the Sonnenalp Resort in ... presentation may include forward-looking information. An audio webcast of ...
(Date:7/31/2015)... 2015 A 10 a. Conferência Internacional ... BGI de 22-25 de outubro de 2015, em ... está celebrando seu 10 o. aniversário este ano. Desde ... das reuniões mais influentes do mundo no ramo das ... e prazerosos. A ICG-10 se concentra ...
Breaking Biology News(10 mins):Innovative Biosensors Incite Use in Non-Traditional Applications 2Innovative Biosensors Incite Use in Non-Traditional Applications 3Innovative Biosensors Incite Use in Non-Traditional Applications 4A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 2A 10a. Conferência Internacional sobre Genômica (ICG-10) será em outubro 3
... identified several genes that are linked to one of the ... researchers describe how three of the genes found in the ... genes drive the development of tumors. The findings appear in ... Genetics . The team was led by researchers from the ...
... of embryonic stem cells to differentiate into different types ... by a complex series of chemical interactions, which are ... prove useful for stem cell-based therapies down the road. ... Zheng zeroes in on the process by which stem ...
... is composed of a nucleus which encloses its genetic information ... membrane separating the cell from the outside world. The impermeability ... the cell from its environment. Although this membrane resistance is ... needs to let in particles necessary for its proper functioning. ...
Cached Biology News:NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 2NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 3NIH researchers identify novel genes that may drive rare, aggressive form of uterine cancer 4Solving stem cell mysteries 2Researchers decipher the mecanism of membrane fission 2
Anti-Dynamin Monoclonal Antibody Description: 100 g Research Focus: neuroscience Storage: -20C Shipping Temperature: 4C...
... Dynabeads Mouse pan B (B220), 4.5 ... For the efficient positive isolation or ... from spleen or lymph node cell ... mouse B cells and lytically active ...
amyotrophic lateral sclerosis 2 (juvenile) chromosome region, candidate 2...
golgi reassembly stacking protein 2, 55kDa...
Biology Products: